Oncternal Therapeutics Inc
$ 0.53
0.00%
04 Mar - close price
- Market Cap 1,558,500 USD
- Current Price $ 0.53
- High / Low $ 0.53 / 0.53
- Stock P/E N/A
- Book Value 3.09
- EPS -11.69
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.76 %
- ROE -1.50 %
- 52 Week High 0.53
- 52 Week Low 0.53
About
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of cancer therapies for cancers with critical unmet medical needs. The company is headquartered in San Diego, California.
Analyst Target Price
$2.00
Quarterly Earnings
| Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-09 | 2023-08-10 | 2023-05-04 | 2023-03-09 | 2022-11-03 | 2022-08-09 | 2022-05-05 | 2022-03-10 |
| Reported EPS | -2.86 | -2.89 | -2.83 | -3.11 | -0.17 | -0.15 | -0.2 | -0.2 | -0.21 | -0.23 | -0.2 | -0.16 |
| Estimated EPS | -3.19 | -3.1 | -2.88 | -3.07 | -0.14 | -0.16 | -0.2 | -0.21 | -0.24 | -0.23 | -0.2 | -0.25 |
| Surprise | 0.33 | 0.21 | 0.05 | -0.04 | -0.03 | 0.01 | 0 | 0.01 | 0.03 | 0 | 0 | 0.09 |
| Surprise Percentage | 10.3448% | 6.7742% | 1.7361% | -1.3029% | -21.4286% | 6.25% | 0% | 4.7619% | 12.5% | 0% | 0% | 36% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ONCT
2025-12-13 12:09:25
Oncternal Therapeutics (NASDAQ: ONCT) is a clinical-stage biopharmaceutical company focused on developing oncology therapies. The company's pipeline includes zilovertamab, ONCT-216, ONCT-808, and ONCT-534, all aimed at various cancers. Recent news indicates the company is winding down operations and voluntarily delisting from Nasdaq.
2025-03-08 05:05:00
Oncternal Therapeutics (Nasdaq: ONCT) announced its intention to voluntarily delist its securities from Nasdaq and subsequently deregister with the SEC. The company will file a Form 25 on March 17, 2025, and then a Form 15 ten days after the Nasdaq delisting becomes effective, which will suspend its obligation to file periodic reports with the SEC. This action follows Nasdaq's suspension of trading of Oncternal's common stock on December 3, 2024.
2025-03-07 03:52:10
Oncternal Therapeutics announced its intention to voluntarily delist its securities from Nasdaq and subsequently deregister with the SEC. The company plans to file a Form 25 on March 17, 2025, which will be followed by a Form 15 filing ten days after Nasdaq delisting becomes effective, suspending its obligation to file periodic reports. Nasdaq had previously suspended trading of Oncternal's stock and notified the company of its intention to file a Form 25, but Oncternal is proceeding voluntarily.
2023-11-02 06:09:19
Oncternal Therapeutics (Nasdaq: ONCT) will report its third-quarter 2023 financial results on Thursday, November 9, 2023, after the U.S. financial markets close. The clinical-stage biopharmaceutical company will hold a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the financial outcomes. Oncternal is focused on developing novel oncology therapies for cancers with critical unmet medical needs, concentrating on hematological malignancies and prostate cancer.
2023-10-28 20:58:50
The FDA has granted Fast Track Designation to ONCT-534, a novel dual-acting androgen receptor inhibitor developed by Oncternal Therapeutics, Inc., for the treatment of relapsed/refractory metastatic castration-resistant prostate cancer (mCRPC) that is resistant to ARPIs. This designation aims to expedite the development and review of ONCT-534, which preclinical studies have shown to exhibit antitumor activity against both unmutated AR and AR alterations. An open-label, single-arm, multicenter phase 1/2 study is currently evaluating the drug's efficacy, pharmacokinetics, and safety in mCRPC patients.
2022-09-07 21:00:00
Oncternal Therapeutics announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference, where its President and CEO, James Breitmeyer, M.D., Ph.D., will present a corporate overview. The presentation will be available on-demand starting September 12th, and the company will hold one-on-one meetings to discuss its novel oncology therapies.
